Pharmacyclics Announces Conference Call to Discuss Fourth Quarter and Full Year 2014 Financial Results

SUNNYVALE, Calif., Feb. 12, 2015 /PRNewswire/ --  Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that it will hold a conference call and audio webcast to discuss its financial results for the fourth quarter and full year 2014 on Wednesday, February 18, 2015 at 4:30 P.M. Eastern Time. A press release of the results will be released shortly after markets close on the day of the conference call.

Interested parties may listen to the live teleconference by calling 877-303-7908 toll free from the U.S. or +1-678-373-0875 internationally. Individuals may access the live audio webcast by visiting: http://ir.pharmacyclics.com/events.cfm.

A webcast replay will be available on the Pharmacyclics website for 30 days following the call.

About Pharmacyclics

Pharmacyclics, Inc. (NASDAQ: PCYC) is a biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. The company's mission is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical needs. It will do so by identifying and controlling promising product candidates based on scientific development and administrative expertise, developing its products in a rapid, cost-efficient manner and, pursuing commercialization and/or development partners when and where appropriate.

Pharmacyclics markets IMBRUVICA and has three product candidates in clinical development and several preclinical molecules in lead optimization. The company is committed to high standards of ethics, scientific rigor and operational efficiency as it moves each of these programs to commercialization. Pharmacyclics is headquartered in Sunnyvale, CA. To learn more, please visit www.pharmacyclics.com.

IMBRUVICA is a registered trademark of Pharmacyclics, Inc.

SOURCE Pharmacyclics, Inc.

Related Links

http://www.pharmacyclics.com